Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Ursula A. Matulonis, MD
|
|
Give Review
Ursula Matulonis is an expert in the field of Oncology. She researched medicine at Albany Medical College. She has 4 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer" and "Super Doctor". Ursula Matulonis is also a published MD. She has 65 publication published. The most recent publication is: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety. Ursula Matulonis accepts Medicare.
Publications
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian Cancer.
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high ...
- Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
- Drug-induced death signaling strategy rapidly predicts Cancer response to chemotherapy.
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial Carcinoma.
- New strategies in ovarian Cancer: translating the molecular complexity of ovarian Cancer into treatment advances.
- Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian Cancer trials.
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian Cancer: a randomised phase 2 study.
- POLE mutations as an alternative pathway for microsatellite instability in endometrial Cancer: Implications for Lynch syndrome testing.
- A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal Carcinoma.
- β-Catenin Mutations in Recurrent FIGO IA Grade I Endometrioid Endometrial Cancers.
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian Cancer: a preplanned retrospective analysis of outcomes by BRCA status in a ra...
- Chemotherapy hypersensitivity reactions in ovarian Cancer.
- PARP inhibitors in ovarian Cancer: Current status and future promise.
- Clinical Predictors of Long-Term Survival for Stage IVB Uterine Papillary Serous Carcinoma Confined to the Abdomen.
- A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial Cancer.
- Ovarian Cancer, version 2.2013.
- Oncogenic mutations in cervical Cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
- Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian Cancer patients.
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ova...
- Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial Cancer.
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal Carcinoma.
- ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian Cancer.
- Hopelessness and Complementary Therapy Use in Patients With Ovarian Cancer.
- Young women diagnosed with early-stage ovarian Cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.
- Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian Cancer.
- New biologic agents for the treatment of gynecologic Cancers.
- Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
- Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era?
- NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
- Urinary MMP-2 and MMP-9 predict the presence of ovarian Cancer in women with normal CA125 levels.
- Epithelial ovarian Cancer.
- High throughput interrogation of somatic mutations in high grade serous Cancer of the ovary.
- CA125 immune complexes in ovarian Cancer patients with low CA125 concentrations.
- Place of death: correlations with quality of life of patients with Cancer and predictors of bereaved caregivers' mental health.
- Influence of patients' preferences and treatment site on Cancer patients' end-of-life care.
- New advances in ovarian Cancer.
- Acupuncture as palliative therapy for physical symptoms and quality of life for advanced Cancer patients.
- Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
- Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
- Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
- Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian Carcinoma.
- Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, Fallopian tube, and peritoneal ...
- Comparison of the quality of life of early and advanced stage ovarian Cancer survivors.
- Acupuncture for chemotherapy-induced Neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.
- Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
- Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian Cancer.
- Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian Cancer.
- Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
- Phase II study of bevacizumab in patients with platinum-resistant ovarian Cancer or peritoneal serous Cancer.
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian Cancer: potential predictive relationship with tumor HER2 activation st...
- A phase II study of irofulven in women with recurrent and heavily pretreated ovarian Cancer.
- Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian Cancer.
- Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
- A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic Cancer: a phase I trial.
- Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
- A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous Cancer, or fallopian tube Cancer.
- Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological Malignancies and mast cell/IgE-mediated reactions.
- End of life issues in older patients.
- Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.
- Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer.
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations.
- Olaparib monotherapy in patients with advanced relapsed ovarian Cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
Schools
Albany Medical College
University Pittsburgh Pa
University Pittsburgh
Dana Farber Cancer Institute
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Brigham and Women's Hospital -
Albany Medical College
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1992870638 | |
| NPPES Provider LastName | MATULONIS | |
| NPPES Provider FirstName | URSULA | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 127.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992870638 |
| Last Name Of The Provider | MATULONIS |
| First Name Of The Provider | URSULA |
| View All |
Similar Doctors
|
|
Dr. Aparna Raj, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Ligibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kinsey A. McCormick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam B. Lerner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pankaj Bhargava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren C. Harshman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel A. Freedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee M. Nadler, MD
This Doctor is OpenDoctor Recommended.
|